Deutsch English Français

Contact

EP2289515

European procedure

Quick help

Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...

News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...

Extract from the Register of European Patents

EP About this file: EP2289515

EP2289515 - Combinations comprising a diaryl urea and an interferon [Right-click to bookmark this link]
Status	The application is deemed to be withdrawn Status updated on 12.04.2013 Database last updated on 05.10.2024
Most recent event Tooltip	12.04.2013	Application deemed to be withdrawn	published on 15.05.2013 [2013/20]
Applicant(s)	For all designated states Bayer HealthCare LLC 555 White Plains Road Tarrytown, NY 10591 / US
	[2011/09]
Inventor(s)	01 / Wilhelm, Scott 29 Masters Lane Milford, CT 06460 / US
	[2011/09]
Representative(s)	Riepe, Hans-Gerd Pfenning, Meinig & Partner GbR Patent- und Rechtsanwälte Theresienhöhe 11a 80339 München / DE
	[N/P]
Former [2011/09]	Riepe, Hans-Gerd Pfenning, Meinig & Partner GbR Patent- und Rechtsanwälte Theresienhöhe 13 D-80339 München / DE
Application number, filing date	10011899.1	31.10.2006
	[2011/09]
Priority number, date	US20050731277P	31.10.2005 Original published format: US 731277 P
	[2011/09]
Filing language	EN
Procedural language	EN
Publication	Type:	A2 Application without search report
	No.:	EP2289515
	Date:	02.03.2011
	Language:	EN
	[2011/09]
	Type:	A3 Search report
	No.:	EP2289515
	Date:	11.04.2012
	Language:	EN
	[2012/15]
Search report(s)	(Supplementary) European search report - dispatched on:	EP	08.03.2012
Classification	IPC:	A61K31/4412, A61K38/21, A61P35/00	[2011/09]
	CPC:	A61K38/21 (EP,US); A61K31/44 (EP,US); A61K38/212 (EP,US); A61P35/00 (EP); A61P43/00 (EP)
	C-Set:	A61K31/44, A61K2300/00 (US,EP); A61K38/212, A61K2300/00 (US,EP); A61K38/21, A61K2300/00 (EP,US)
Designated contracting states	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR [2011/09]
Extension states	AL	Not yet paid
	BA	Not yet paid
	HR	Not yet paid
	MK	Not yet paid
	RS	Not yet paid
Title	German:	Kombinationen enthaltend einen Diarylharnstoff und einen Interferon	[2011/09]
	English:	Combinations comprising a diaryl urea and an interferon	[2011/09]
	French:	Combinaison contenant une diaryl urée et un interferon	[2011/09]
Examination procedure	12.10.2012	Application deemed to be withdrawn, date of legal effect [2013/20]
	19.11.2012	Despatch of communication that the application is deemed to be withdrawn, reason: examination fee not paid in time [2013/20]
Parent application(s) Tooltip	EP06827111.3 / EP1968589
Divisional application(s)	The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued (EP20060827111) is 02.10.2008
Fees paid	Renewal fee
	30.09.2010	Renewal fee patent year 03
	30.09.2010	Renewal fee patent year 04
	30.09.2010	Renewal fee patent year 05
	11.10.2011	Renewal fee patent year 06
	Penalty fee
	Additional fee for renewal fee
	31.10.2012	07 M06 Not yet paid
Opt-out from the exclusive Tooltip competence of the Unified Patent Court	See the Register of the Unified Patent Court for opt-out data
	Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:	Search	[XY]WO2004113274 (BAYER PHARMACEUTICALS CORP [US], et al) [X] 1-9 * p.89: compound 42 * * page 22, lines 12-22 * * page 41, lines 3-12 * [Y] 1-9;
		[IP]WO2006094626 (BAYER HEALTHCARE AG [DE], et al) [IP] 1-9 * claim 1 * * page 3, lines 15-22 * * page 14, line 6 *;
		[IP]WO2006034797 (BAYER HEALTHCARE AG [DE], et al) [IP] 1-9 * claim - * * examples 1,2 * * page 10, line 24 *
		[I] - "883 POSTER Phase I trial of sorafenib (BAY 43-9006) in combination with interferon alpha-2a in patients with unresectable and/or metastatic renal cell carcinoma and malignant melanoma", EUROPEAN JOURNAL OF CANCER. SUPPLEMENT, PERGAMON, OXFORD, GB, (200510), vol. 3, no. 2, ISSN 1359-6349, page 254, XP005132997 [I] 1-9 * the whole document *
		[I] - "795 ORAL Phase II trial of sorafenib (BAY 43-9006) in combination with interferon alpha 2b in patients with metastatic renal cell carcinoma", EUROPEAN JOURNAL OF CANCER. SUPPLEMENT, PERGAMON, OXFORD, GB, (200510), vol. 3, no. 2, ISSN 1359-6349, pages 226 - 227, XP005132909 [I] 1-9 * the whole document *
		[Y] - AHMAD T ET AL, "Kinase inhibition with BAY 43-9006 in renal cell carcinoma", CLINICAL CANCER RESEARCH, THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, (20040319), vol. 10, no. 18 Pt 2, ISSN 1078-0432, pages 6388S - 6392S, XP002362669 [Y] 1-9 * abstract * * page 6390S, column L, lines 14-23 * DOI: http://dx.doi.org/10.1158/1078-0432.CCR-040028
	by applicant	WO9404157
		US5023252
		US5011472
		WO0042012
		WO0041698
		WO9800402
		EP0542609
		DE2436108
		US2002042517
		WO02085859
		WO02085857
		- S. M. BERGE ET AL., "Pharmaceutical Salts", J PHARM. SCI., (1977), vol. 66, doi:doi:10.1002/jps.2600660104, pages 1 - 19, XP002675560 DOI: http://dx.doi.org/10.1002/jps.2600660104
		- WILLIAMS & WILKINS ET AL., PHARMACEUTICAL DOSAGE FORM AND DRUG DELIVERY SYSTEMS, (1995), pages 27 - 29
		- Goodman and Gilman's The Pharmacological Basis of Therapeutics, MCGRAW-HILL, (1996), pages 11 - 13
		- GOODMAN ET AL., Gilman's The Pharmacological Basis of Therapeutics, MCGRAW-HILL, (1996), pages 1225 - 1287
		- Organic Reactions, JOHN WILEY
		- Organic Syntheses, JOHN WILEY
		- Reagents for Organic Synthesis, JOHN WILEY
		- The Total Synthesis of Natural Products, JOHN WILEY
		- The Organic Chemistry of Drug Synthesis, JOHN WILEY
		- Annual Reports in Organic Synthesis, ACADEMIC PRESS
		- Methoden der Organischen Chemie, HOUBEN-WEYL
		- POWELL, M.F. ET AL., "Compendium of Excipients for Parenteral Formulations", PDA JOURNAL OF PHARMACEUTICAL SCIENCE & TECHNOLOGY, (1998), vol. 52, no. 5, pages 238 - 311, XP009119027
		- STRICKLEY, R.G, "Parenteral Formulations of Small Molecule Therapeutics Marketed in the United States (1999)-Part-l", PDA JOURNAL OF PHARMACEUTICAL SCIENCE & TECHNOLOGY, (1999), vol. 53, no. 6, pages 324 - 349
		- NEMA, S. ET AL., "Excipients and Their Use in Injectable Products", PDA JOURNAL OF PHARMACEUTICAL SCIENCE & TECHNOLOGY, (1997), vol. 51, no. 4, pages 166 - 171
		- POWELL, M.F., "Compendium of Excipients for Parenteral Formulations", PDA JOURNAL OF PHARMACEUTICAL SCIENCE & TECHNOLOGY, (1998), vol. 52, no. 5, pages 238 - 311, XP009119027
		- STRICKLEY, R.G, "Parenteral Formulations of Small Molecule Therapeutics Marketed in the United States (1999)-Part-1", PDA JOURNAL OF PHARMACEUTICAL SCIENCE & TECHNOLOGY, (1999), vol. 53, no. 6, pages 324 - 349
		- NEMA, S., "Excipients and Their Use in Injectable Products", PDA JOURNAL OF PHARMACEUTICAL SCIENCE & TECHNOLOGY, (1997), vol. 51, no. 4, pages 166 - 171
		- RIEDL, B. ET AL., "O-Carboxy Aryl Substituted Diphenyl Ureas as raf Kinase Inhibitors", PCT INT. APPL.
		- RIEDL, B. ET AL., "O-Carboxy Aryl Substituted Diphenyl Ureas as p38 Kinase Inhibitors", PCT INT. APPL.
		- BANKSTON ET AL., "A Scaleable Synthesis of BAY 43-9006: A Potent Raf Kinase Inhibitor for the Treatment of Cancer", ORG. PROC. RES. DEV., (2002), vol. 6, no. 6, doi:doi:10.1021/OP020205N, pages 777 - 781, XP002524977 DOI: http://dx.doi.org/10.1021/OP020205N
		- IBID BIOORG. MED. CHEM., (1995), vol. 3, page 129
		- CHEMICAL ABSTRACTS, Database accession no. 12761B
		- IBID KOGYO KAGAKU ZASSHI, (1967), vol. 70, page 491
		WO2004US15655
		US20010948915
		US20040556062
		US19990605203
		US20030471735

The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.

Legal notice
Terms of use
24.2.25; 35p